Page 33 - Children Bookt.pdf
P. 33
K0>!! &>@#! 2
PQ%!
6
^
&
++!
&
infant ARVs is unknown, is to start standard NVP-containing triple therapy.
}&*/
+/6$
^
&
+/
NVP + 3TC + AZT
+!
'
+/
++!@}&`
$
inhibitor drugs prevent HIV replication by inhibition of the action of reverse
transcriptase, the enzyme that HIV uses to make a DNA copy of its RNA. EFV is
not currently recommended for use in children less than 3 years of age due to lack of
information on appropriate dosing.
}&*/
++!6
&
^
LPV/r + 3TC + AZT
$
'
the above recommendation to be strong, they also recognized that in many resource-
limited settings, LPV/r is not available, affordable or, due to cold chain requirements,
'
!
?/"6
may compromise the potential to construct a potent second- line regimen.
*Q%!
6
!6
^
+!
++!@}&`
&
*
Z]
should be avoided in adolescent girls (due to the teratogenic potential of EFV in the
`
x
@
appropriate dosing information in this age group). See Table (10) for a summary of
6
`
The use of a triple NRTI regimen (i.e. [AZT or d4T] + 3TC + ABC) can be considered
@
}&x`G
the somewhat lower virological potency of this regimen compared with a two-class
triple-drug combination in adult studies. Currently, a triple NRTI regimen is only
recommended in children less than three years of age who are receiving treatment for
TB, a situation where NVP may not be an optimal choice because of drug interactions
with rifampicin. This regimen could be considered for adolescents who may become
pregnant, or adolescents with anticipated or documented poor adherence.
25
